Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAFV600-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600-mutant melanoma and brain metastasis (BM) and explored if radiotherapy improves the duration of respo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (11), p.2074-2083
Hauptverfasser:	Márquez-Rodas, Iván, Álvarez, Ana, Arance, Ana, Valduvieco, Izaskun, Berciano-Guerrero, Miguel-Ángel, Delgado, Raquel, Soria, Ainara, Lopez Campos, Fernándo, Sánchez, Pedro, Romero, Jose Luis, Martin-Liberal, Juan, Lucas, Anna, Díaz-Beveridge, Roberto, Conde-Moreno, Antonio-José, Álamo de la Gala, Maria Del Carmen, García-Castaño, Almudena, Prada, Pedro José, González Cao, María, Puertas, Enrique, Vidal, Joana, Foro, Palmira, Aguado de la Rosa, Carlos, Corona, Juan Antonio, Cerezuela-Fuentes, Pablo, López, Paco, Luna, Pablo, Aymar, Neus, Puértolas, Teresa, Sanagustín, Pilar, Berrocal, Alfonso
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzimidazoles - administration & dosage Benzimidazoles - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Carbamates - administration & dosage Carbamates - therapeutic use Chemoradiotherapy - methods Clinical Investigations Female Follow-Up Studies Humans Male Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Melanoma - radiotherapy Middle Aged Mutation Prognosis Prospective Studies Proto-Oncogene Proteins B-raf - genetics Sulfonamides - administration & dosage Sulfonamides - therapeutic use Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!